Literature DB >> 30532804

A fatal complication of tirofiban in an octogenarian: Diffuse alveolar hemorrhage.

Erkan İlhan1, Tolga Sinan Güvenç1, Özge Güzelburç1, Servet Altay1, Nihat Özer1, Özer Soylu1, Hakan Hasdemir1, Mehmet Ergelen1.   

Abstract

An 84-year-old female patient with a past medical history significant for hypertension and diabetes mellitus, was admitted to the Emergency Department with acute coronary syndrome and complete atrioventricular block. She underwent a successful primary percutaneous coronary intervention. Ten minutes following tirofiban administration, the patient complained of hemoptysis and severe dyspnea. After chest X-ray and diagnostic bronchoscopy, she was diagnosed with diffuse alveolar hemorrhage. She died because of respiratory insufficiency on the third day of hospitalization. We present the first tirofiban-related diffuse alveolar hemorrhage case caused with half of the recommended dose of tirofiban used in the setting of non-ST-elevation myocardial infarction.

Entities:  

Keywords:  Acute coronary syndrome; Diffuse alveolar hemorrhage; Glycoprotein IIb/IIIa antagonist; Tirofiban

Year:  2010        PMID: 30532804      PMCID: PMC6265041          DOI: 10.1016/j.jccase.2010.02.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  11 in total

1.  Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication.

Authors:  Mehmet Birhan Yilmaz; Yesim Akin; Senay Funda Biyikoglu; Umit Guray; Sule Korkmaz
Journal:  Int J Cardiol       Date:  2004-01       Impact factor: 4.164

Review 2.  Alveolar hemorrhage associated with platelet glycoprotein IIb/IIIa receptor inhibitors.

Authors:  Rasih Atilla Ener; Nichole Bruno; Daniel Dadourian; Nelson Wolf; William Van Decker; James Burke; Michael Styler; David Topolsky
Journal:  J Invasive Cardiol       Date:  2006-06       Impact factor: 2.022

3.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

4.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams
Journal:  Circulation       Date:  2009-11-18       Impact factor: 29.690

Review 5.  Safe use of platelet GP IIb/IIIa inhibitors.

Authors:  J J Ferguson; D J Kereiakes; A A Adgey; K A Fox; W B Hillegass; M Pfisterer; C Vassanelli
Journal:  Eur Heart J       Date:  1998-04       Impact factor: 29.983

6.  Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.

Authors:  A Ali; S Patil; K J Grady; T L Schreiber
Journal:  Catheter Cardiovasc Interv       Date:  2000-02       Impact factor: 2.692

7.  Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.

Authors:  Said B Iskandar; Ehab S Kasasbeh; Bassam K Mechleb; Israel Garcia; Ann Jackson; Stephen Fahrig; Kaiss Albalbissi; Phillip D Henry
Journal:  J Interv Cardiol       Date:  2006-08       Impact factor: 2.279

8.  Alveolar hemorrhage as a complication of treatment with abciximab.

Authors:  S Kalra; M R Bell; C S Rihal
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

9.  Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage.

Authors:  Arshad Ali; Mustafa Hashem; Howard S Rosman; Ghassan Kazmouz; Julius M Gardin; Theodore L Schrieber
Journal:  J Invasive Cardiol       Date:  2003-04       Impact factor: 2.022

10.  Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.

Authors:  D S Gill; K Ng; K-S Ng
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

View more
  2 in total

Review 1.  Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.

Authors:  Jincheng Guo; Min Xu; Yutao Xi
Journal:  Tex Heart Inst J       Date:  2012

2.  Salvianolic acid A protects against myocardial ischemia/reperfusion injury by reducing platelet activation and inflammation.

Authors:  Xiaoling Yuan; Yijia Xiang; Ning Zhu; Xuyong Zhao; Shiyong Ye; Peng Zhong; Chunlai Zeng
Journal:  Exp Ther Med       Date:  2017-06-15       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.